Contera Pharma
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Contera Pharma
Deal Watch: Revance To Go Private In Crown Laboratories Buyout
Plus deals involving AstraZeneca/Conduit, Recursion/Exscientia, G1/Pharmacosmos, Sanofi/Vir, Passage Bio/GEMMA and Lupin/Evofem. Also including deals in brief.
Deal Watch: Lilly Partners With OpenAI On Drug-Resistant Pathogens
Plus transactions involving ANI/Alimera, Gilead/ashibio, Sanofi/Belharra and more.
Bukwang Adds To Stacking Mid-Stage Failures In Parkinson's
Bukwang and subsidiary Contera have become the latest to fail to progress a novel Parkinson's therapy to late-stage trials after a Phase II miss, although several other Korean firms remain in the race for the challenging indication, albeit mainly in Phase I-II.
Finance Watch: Big Money In Post-Data Follow-On Offerings
Public Company Edition: Insmed grossed $650m, Structure raised $476m and Merus brought in $400.2m after positive clinical trial results. But while CARGO raised $110m in a private placement and Day One sold a priority review voucher for $108m, Ikena, Takeda and others cut jobs.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
- Other Names / Subsidiaries
-
- Concit Pharma ApS
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice